Pharmacogenetics in cardiovascular disorders: An update on the principal drugs
dc.contributor.author | Predazzi, I. | |
dc.contributor.author | Mango, R. | |
dc.contributor.author | Norata, Giuseppe | |
dc.contributor.author | Di Daniele, N. | |
dc.contributor.author | Sergi, D. | |
dc.contributor.author | Romeo, F. | |
dc.contributor.author | Novelli, G. | |
dc.date.accessioned | 2017-08-24T02:20:53Z | |
dc.date.available | 2017-08-24T02:20:53Z | |
dc.date.created | 2017-08-23T07:21:47Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Predazzi, I. and Mango, R. and Norata, G. and Di Daniele, N. and Sergi, D. and Romeo, F. and Novelli, G. 2013. Pharmacogenetics in cardiovascular disorders: An update on the principal drugs. American Journal of Cardiovascular Drugs. 13 (2): pp. 79-85. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/55833 | |
dc.identifier.doi | 10.1007/s40256-013-0020-9 | |
dc.description.abstract |
In the coming years, genomics will impact clinical practice in multiple ways. However, one of the most important applications will be in the determination of the best treatments in personalized medicine. This is, in fact, one of the fields in which genetic variants have already been most successful and useful to clinicians. Here, we briefly review the current state of the art on pharmacogenomics and its applications to modern cardiovascular medicine. © 2013 Springer International Publishing Switzerland. | |
dc.title | Pharmacogenetics in cardiovascular disorders: An update on the principal drugs | |
dc.type | Journal Article | |
dcterms.source.volume | 13 | |
dcterms.source.number | 2 | |
dcterms.source.startPage | 79 | |
dcterms.source.endPage | 85 | |
dcterms.source.issn | 1175-3277 | |
dcterms.source.title | American Journal of Cardiovascular Drugs | |
curtin.department | School of Biomedical Sciences | |
curtin.accessStatus | Fulltext not available |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |